Diskusjon Triggere Porteføljer Aksjonærlister

Gentian Diagnostics

Biotek
#683

Beyond creatinine: Why labs and clinicians should incorporate cystatin C for kidney assessment

Recent clinical guidelines for kidney management, e.g. KIDIGO 2024, and a growing body of evidence are driving broader adoption of cystatin C alongside creatinine testing in chronic kidney disease (CKD) care and medication dosing

Updated international guidelines and a growing body of evidence now support using cystatin C, either alone or combined with creatinine, to improve the accuracy and reliability of GFR assessment. Organizations such as KDIGO, the National Kidney Foundation (NKF), the American Society of Nephrology (ASN), the U.S. Department of Veterans Affairs, and the European Kidney Function Consortium increasingly recommend cystatin C for selected patient populations, including older adults, patients with low or high muscle mass, individuals with chronic illness or malnutrition, patients with obesity, cancer patients, transplant recipients, and frail or hospitalized patients.

2 Likes
#684

Flere artikler siste uken rundt Cystatin C. Ser ut som The Lancet har gående en serie på tre artikler hvor første ble publisert forrige uke.

Advances in the diagnosis and detection of chronic kidney disease

Chronic kidney disease affects 788–844 million adults worldwide and is projected to become the fifth leading cause of death by 2040. Global burden estimates remain limited by ascertainment bias and inadequate access to testing, particularly in low-income and middle-income countries. Advances in detection include improved estimation of glomerular filtration rate (GFR) using cystatin C and the recognition of albuminuria as a key marker for screening and risk stratification.

What should clinicians and health systems do differently now?
For clinical practice
• Use cystatin C under recommended conditions
• Screen for albuminuria according to guidelines
• Apply recommended risk prediction models during nephrology referral, patient counselling, and kidney replacement therapy preparation

Population-wide CKD screening using estimated glomerular filtration rate and albuminuria is cost-effective, and can reduce lifetime risk of kidney replacement therapy and cardiovascular disease. (…) cost-effective in all countries studied.

Cystatin C (…) offers a stronger indicator of risk than eGFR based on creatinine alone

Faktisk er også calprotectin nevnt:

image
image1051×240 63.1 KB

image
image1044×58 12.3 KB

Og en artikkel fra Kina rundt forskning på Alzheimers hvor Cystatin C kan spille en rolle som terapeutikum. Da vil i så fall måling av Cystain C bli aktuelt.

Observational data has long hinted at an intriguing inverse relationship between cancer and Alzheimer’s disease (AD), where individuals with a history of certain cancers appear less likely to develop AD. This phenomenon puzzled scientists, prompting investigations into potential protective mechanisms

the research demonstrates how tumors secrete a protein called cystatin C (Cyst-C), a natural cysteine protease inhibitor produced by various cell types including tumor cells. This protein crosses the blood-brain barrier (BBB), targets amyloid-beta (Aβ) oligomers—toxic protein aggregates central to AD pathology—and activates microglia, the brain’s immune cells, to clear plaques effectively.

5 Likes
#685

Et element rundt bruken av GLP-1 er at personer med betydelig vekttap får endret muskelmasse, og muskelmasse påvirker kreatinin. Cystatin C er ikke påvirket av muskelmasse, i motsetning til kreatinin, og det vil igjen vil være et argument for å bruke Cystatin C.

Accordingly, trials that include therapies that induce significant weight loss should consider inclusion of cystatin C–based eGFR estimates, because direct measured GFR levels pose logistic challenges in large-scale trials.

Where possible, the use of both creatinine- and cystatin C–based eGFR equations should be considered, particularly when agents may affect muscle metabolism, potentially increasing the variability of serum creatinine levels

I tillegg indirekte om hjertesvikt

These paradoxical findings may be due, in part, to the inherent limitations of serum creatinine as a biomarker in the setting of acute decompensated HF: its production is affected by muscle mass; it is intended to be interpreted in steady state; and it may manifest a delayed response to dynamic changes in kidney function.

Therefore, the evidence for using serum creatinine to guide therapy in acute decompensated HF to improve clinical outcomes is modest at best, and studies have shown that both improvement and worsening of serum creatinine are associated with poor clinical outcomes.

For Calprotectin blir det spennende med JIA-COMPASS studien til Gentian med resultater Q2/Q3:

Prospective JIA-COMPASS study
The JIA-COMPASS study evaluating GCAL in
children with juvenile idiopathic arthritis (JIA) is progressing according to plan. A total of 131 patients has been enrolled across Croatia, Turkey and Romania, and Spain is preparing to initiate enrolment. Preliminary analysis of collected samples is expected in Q2’26, with initial results planned for presentation at the PRES (Paediatric Rheumatology European Society) annual meeting in September. The study is designed to generate biomarker-based insights supporting earlier diagnosis, improved disease monitoring and more personalised treatment approaches in JIA

2 Likes
#686

ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT

2 Likes
#687

Altså en intensjonsavtale… non-event nærmest.

#688

95% av avtaler som blir meldt intensjon på ender vel opp med å bli signert, så det er nå en ting.

Men man aner jo ikke om det kommer noe business ut av det til slutt enda.

#689

Fin mulighet dette. Tipper de har jobbet en stund allerede med lavthengendefrukt tester, konvertering eksisterende fra elisa til automatisert, og distribusjon via kjente oem kanaler. Håper det kan forklares og kvantifiseres i en cmd i aug/sep. Kan også komme tilsvarende med Siemens/BC/Abott?

#690

For all del; bra med samarbeid hvis/når det materialiseres. Men hva er poenget med å annonsere dette nå?

Se til dagens Circio-melding. Hva hadde blitt sagt om de i stedet meldte:

“Circio and Tcelltech jointly announce intention to enter into a CAR-T cell therapy research collaboration”

For øvrig med tanke på Vatne sin tidligere aksjepost.

I 2022 kjøpte Gilde Healthcare en majoritetspost i Essange Reagents.

Gilde Healthcare driver både Venture&Growth fund og Private Equity:

The Venture&Growth fund is focused on:

  • Healthtech and therapeutics
  • Early revenue stage or clinical development stage
  • Equity investments of up to €50 million per portfolio company
  • Europe and North America
  • Significant minority ownership

The Private Equity fund is focused on:

  • Pharma & life sciences, Medtech & Diagnostics, Healthcare Providers, Healthcare IT & Outsourced services
  • Established and profitable businesses with an EBITDA between €2-15 million
  • Primarily Northwestern Europe
  • Preference for majority ownership
2 Likes
#691

Skjer her da? Plutselig litt omsetning og stigende kurs. Forventninger til Q1?

1 Like
#692

Lukter det og/eller at DnB posten nærmer seg plassering mot kvalitet investor

#693

Gaute Tangen, produkt leder i Gentian, skrev nylig følgende på sin LinkedIn side:
“ADLM is just around the corner-and the growth of cystatin C is stronger than ever, with more hospitals adopting the assay in-house!”
Sammen med Kina return i q2, ordreforskyvelse fra q1, så tyder dette på veldig solid CC kvartal. Fcal blir nok også sterkt med nye Buhlmannavtalen i q1 (sannsynligvis volum incentivert). Om øvrige produkter også løfter seg og brutto margin kommer opp mot 60% igjen, så kan q2 bli veldig solid.

2 Likes
#694

Hvis hele ordreforskyvelsen havner i Q2 sammen med et “forventet” øvrig resultat kan dette bli bra. Gentian må nesten levere >godkjent dette kvartalet da det er viktigere enn på lenge: Både for å vise at kjernevirkshomheten leverer som den skal, pluss tiltrekke seg investorer, eller best case → M&A.

Cystatin C order worth NOK 5.3 million pushed to subsequent quarters , with no expected negative impact on full‑year sales

3 Likes
#695

Kan Runar Vatne måtte selge aksjer for å hindre tvangssalg av eiendom?

#696

Han har igjen 220 000 aksjer i selskapet Lioness - den store posten er overtatt av DNB i mai.

#697

Tvangsovertatt av DNB for å selges antagelig.
Finner de kjøper til en ikke alt for stor rabatt?

#698

husker ikke hvor i farta, men det var noen som plukket opp DNB si at de har god tid med å avhende denne posten.

#699

Gentian Diagnostics: Invitation to presentation of second quarter results

#700

Blir spennende med Q2 i morgen :crossed_fingers:

#701

Gentian Diagnostics - Second quarter 2026 report

2 Likes
#702

Godkjent dette.

20% organisk vekst
EBITDA 8.1 mnok
Bühlman og fCal leverer som bare det
Cystatin C svak pga Asia, men USA kompenserer. Endelig subtsansiell vekst derfra på 45%

image
image1282×700 161 KB

image
image1242×694 182 KB

3 Likes